Status and phase
Conditions
Treatments
About
this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main study IP-005.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Criteria for Exclusion: Patients are excluded from participating in this study if 1 or more of the following criteria are met:
Primary purpose
Allocation
Interventional model
Masking
62 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal